Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from chronic obstructive pulmonary disease (COPD), asthma and other respiratory diseases. This technology provides a novel combination of sensors, mobile applications, data analytics and personalised feedback, encouraging patient adherence to maintenance therapy. The Propeller Health device and technology has been used by patients with respiratory diseases in over 40 commercial programmes across the US, including major healthcare systems, payers and employers. The Propeller Health device is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers, and other inhaler devices (dry powder inhaler and soft mist inhaler). Propeller has partnered with several companies including Vectura Group to develop an add-on sensor for Vectura’s lever-operated multi-dose inhaler.

Hikma Ventures’ investment will be supporting the expansion of Propeller Health’s digitally guided therapy platform and modernise the management of respiratory disease. The market size for digital dose inhalers for asthma and COPD is expected to reach around $3.6 billion in 2024.

Lana Ghanem, Managing Director of Hikma Ventures, said: “Our investment in Propeller Health demonstrates our focus on identifying and investing in innovative, high potential digital health providers. We are very excited to be supporting the development of Propeller’s technology platform, which is enabling physicians, patients and providers to have advanced access to better quality data as well as improved medication adherence in the growing respiratory segment.”

David Van Sickle, CEO of Propeller Health, said, “Despite an abundance of effective treatments, the majority of people with chronic respiratory disease could be doing much better than they are. We’re excited to work with Hikma Ventures on our efforts to develop information-powered medicines that help people and their physicians achieve control of these conditions.”